GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

What is the purpose of this trial?

The investigators plan to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide versus placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. Additionally, the investigators plan to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug.


Participation Guidelines

Ages: 18 - 50 years

Gender: Both


Yale University School of Medicine

Dates: 11/21/2014 - 11/30/2019

Last Updated: 03/29/2017

Study HIC#: 1409014655

Get Involved

For more information about this study, contact:
Jessica Costeines
203-520-6398
jessica.costeines@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Robert T. Malison

Principal Investigator

Sub-Investigators